Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

QNRXBullishIndustry Newsnews

High materiality9/10

QRX003 advances with PSS trial, EU exclusivity, and FDA designations

Oct 14, 2026, 6:42 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive regulatory milestones and imminent trial initiation are near-term catalysts that could drive upside risk-adjusted valuation if progress continues; lack of revenue yet keeps downside limited to development delays.

AI summary

What happened, with direct paths to the underlying reporting

Quoin Pharmaceuticals reports QRX003 progress for Peeling Skin Syndrome (PSS) with a first formal trial planned before year-end. EU Orphan Drug designation provides 10 years of market exclusivity post-approval, while US FDA Pediatric Rare Disease and Fast Track designations support development velocity. The program also shows expanded orphan and fast-track designations for Netherton Syndrome across US, Europe and Japan, underscoring broad regulatory momentum.

QNRX003 to start first-ever formal PSS trial before year-end. EU Orphan Drug yields 10-year exclusivity after approval.
QRX003 eighth regulatory milestone; FDA Pediatric Rare Disease and Fast Track for PSS.
In Netherton Syndrome, QRX003 holds Orphan Drug designation US/Europe/Japan plus US pediatric rare disease and Fast Track designations.
Overall progress boosts regulatory credibility and potential value upside for QRX003.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

QRX003 advances with PSS trial, EU exclusivity, and FDA designations

Quoin Raises Up To $50 Million to Fund QRX003, Extending Runway into 2029